Carol Gallagher, Pharm.D. is an experienced board director having served as a director in both public and private companies since 2011. From 1989 to 2011, Dr. Gallagher enjoyed a successful and varied career in both large and small biopharmaceutical companies. She started her career in sales and marketing at Eli Lilly and held various positions of increasing responsibility in commercial, drug development and business development at companies such as Amgen, Agouron Pharmaceuticals, Pfizer, and IDEC Pharmaceuticals.
Starting in 2008, Dr. Gallagher was President and CEO of Calistoga Pharmaceuticals where she led the development of first-in-class cancer therapeutic, ZYDELIG. Calistoga Pharmaceuticals was acquired by Gilead in 2011, and ZYDELIG was approved in the US and EU in 2014. She currently serves as a Venture Partner at New Enterprise Associates whom she represents as a director on four private company boards. In addition to Certara, she is a director at Turning Point Therapeutics (TPTX), Atara Biotherapeutics (ATRA), and Frazier Life Sciences Acquisition (FLACU). She has experience chairing Audit, Compensation, and Nominating and Governance committees. Dr. Gallagher attended Vanderbilt University and received Bachelor of Science and Doctor of Pharmacy degrees from the University of Kentucky College of Pharmacy.